About Luye Pharma
Luye Pharma is a company based in Shanghai (China) founded in 1994. It operates as a Direct-to-Consumer (D2C). The company has 5,150 employees as of December 31, 2024. Luye Pharma has completed 1 acquisition, including A-Bio Pharma. Luye Pharma offers products and services including Ruoxinlin®, LY03021, and Rykindo®.
- Headquarter Shanghai, China
- Employees 5150 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Luye Pharma Group Ltd.
-
Annual Revenue
$845.94 M (USD)-3.18as on Dec 31, 2024
-
Net Profit
$65.88 M (USD)-13.07as on Dec 31, 2024
-
EBITDA
$271.68 M (USD)17.77as on Dec 31, 2024
-
Latest Funding Round
$161.21 M (USD), Post-IPO
Jan 31, 2021
-
Investors
Hillhouse
& 1 more
-
Employee Count
5150
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Luye Pharma
Luye Pharma is a publicly listed company on the HKEX with ticker symbol 2186 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Luye Pharma
Luye Pharma offers a comprehensive portfolio of products and services, including Ruoxinlin®, LY03021, and Rykindo®.
Innovative drug used for depression and anxiety treatment.
Innovative antidepressant drug under clinical research phase.
Innovative drug launched for international market access.
Funding Insights of Luye Pharma
Investors in Luye Pharma
Luye Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Hillhouse and Ardian.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked | |
|
Private investment firm specializing in markets and partnerships.
|
Locked | Locked | Locked |
Investor details for Luye Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Luye Pharma
Luye Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include A-Bio Pharma.
Investment portfolio details for Luye Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Mammalian cell-line development services are provided for biopharmaceutical needs.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for Luye Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Luye Pharma
Detailed financials for Luye Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Luye Pharma Comparisons
Peer comparison for Luye Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Luye Pharma
Detailed competitors of Luye Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Luye Pharma
Complete news archive for Luye Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Luye Pharma
Luye Pharma was founded in 1994 and raised its 1st funding round 18 years after it was founded.
Luye Pharma is headquartered in Shanghai, China.
As of Dec 31, 2024, the latest employee count at Luye Pharma is 5,150.
Annual revenue of Luye Pharma is $845.94M as on Dec 31, 2024.
Luye Pharma Group Ltd. is involved in the research, development, production, and sales of innovative pharmaceuticals. The company operates internationally, focusing on therapeutic areas such as depression and anxiety disorders. Solutions are provided through products like Ruoxinlin and Rykindo, targeting global healthcare markets. The group serves various sectors within the pharmaceutical industry, emphasizing innovation and clinical advancements.
Luye Pharma offers Ruoxinlin®, LY03021, and Rykindo®.
Yes, Luye Pharma is publicly traded on HKEX under the ticker symbol 2186.
Luye Pharma has made 1 acquisition, including A-Bio Pharma.
The ticker symbol of Luye Pharma is 2186 on HKEX.